/
Oncology
Liposarcoma
12
Pipeline Programs↗
20
Active Trials↗
24
Companies Involved↗
Liposarcoma is an emerging landscape with 12 programs across 24 companies. The most active players are Ascentage Pharma Group Inc., Pfizer, Edgewood Oncology Inc.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 14
Phase 27
Phase 31
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
9 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
48
clinical trials
Completed18 · 38%
Recruiting9 · 19%
Active, not recruiting9 · 19%
Terminated6 · 13%
Unknown status3 · 6%
Not yet recruiting2 · 4%
Other1 · 2%
Clinical Trials
Trial Activity
48 trials
SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
Active, not recruiting·SSarcoma Alliance for Research through Collaboration·Phase 3·NCT04967521·108 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)